Lord, Abbett & Co’s MyoKardia, Inc. Common Stock MYOK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-319,511
| Closed | -$43.6M | – | 719 |
|
|
2020
Q3 | $43.6M | Buy |
319,511
+123,064
| +63% | +$13.1M | 0.14% | 236 |
|
|
2020
Q2 | $19M | Buy |
+196,447
| New | +$16.4M | 0.07% | 382 |
|
|
2020
Q1 | – | Sell |
-145,569
| Closed | -$10.6M | – | 727 |
|
|
2019
Q4 | $10.6M | Sell |
145,569
-29,950
| -17% | -$1.82M | 0.04% | 509 |
|
|
2019
Q3 | $9.15M | Sell |
175,519
-12,720
| -7% | -$676K | 0.03% | 543 |
|
|
2019
Q2 | $9.44M | Sell |
188,239
-11,383
| -6% | -$554K | 0.03% | 566 |
|
|
2019
Q1 | $10.4M | Sell |
199,622
-4,654
| -2% | -$214K | 0.03% | 553 |
|
|
2018
Q4 | $9.98M | Sell |
204,276
-38,674
| -16% | -$2.13M | 0.04% | 540 |
|
|
2018
Q3 | $15.8M | Buy |
242,950
+19,593
| +9% | +$1.15M | 0.04% | 523 |
|
|
2018
Q2 | $11.1M | Sell |
223,357
-4,297
| -2% | -$208K | 0.03% | 604 |
|
|
2018
Q1 | $11.1M | Sell |
227,654
-534
| -0.2% | -$27.8K | 0.03% | 602 |
|
|
2017
Q4 | $9.61M | Buy |
228,188
+23,285
| +11% | +$897K | 0.03% | 626 |
|
|
2017
Q3 | $8.78M | Buy |
+204,903
| New | +$6.54M | 0.03% | 657 |
|
Lord, Abbett & Co's MYOK Position: Q4 2020 in Review
Lord, Abbett & Co sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 319,511 shares — an estimated $43.6M sold.
Lord, Abbett & Co first reported a position in MYOK in Q3 2017 and held it in 12 quarters. The position peaked at $43.6M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.
- Lord, Abbett & Co reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
- Lord, Abbett & Co sold 319,511 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $43.6M.
- Lord, Abbett & Co first reported a position in MyoKardia, Inc. Common Stock in Q3 2017 and held it in 12 quarters.
- Lord, Abbett & Co's MyoKardia, Inc. Common Stock position peaked at $43.6M in Q3 2020.
- 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.
Based on Lord, Abbett & Co's 13F filing for Q4 2020, filed 9 Feb 2021.